What ails Divi’s?
Finshots Daily
00:00
Devi's Custom Synthesis - Should Investors Be Worried?
Devi's custom synthetic share had jumped to nearly 60% of its business in FY 22, it has fallen back again to just 40%. Investors were disappointed. They had bought the stock in anticipation that these good times will continue. And the thing is, Devi's custom synthesis business isn't in its control. The pharma giants actively creating new drugs and running clinical trials ebbs and flows. It's not immune to short term variations.
Play episode from 05:06
Transcript
